Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase II dose-to-rash study of Tarceva

Nov. 12, 2003

Eligard products receive Canadian approval

Nov. 12, 2003

Hybrigenics and Servier sign new drug discovery agreements

Nov. 11, 2003

New ErbB kinase inhibitors, their preparation and use revealed in AstraZeneca patent

Nov. 11, 2003

BMS researchers present new protein kinase inhibitors for proliferative and inflammatory disorders

Nov. 11, 2003

Xcytrin evaluated in combination with Rituxan and Zevalin

Nov. 10, 2003

New EGFR inhibitors discovered at Boehringer Ingelheim

Nov. 10, 2003

Good efficacy and safety profile reported for arzoxifene in hormone-sensitive breast cancer

Nov. 10, 2003

Troxacitabine safety and efficacy in CML-BP

Nov. 7, 2003

Oral topoisomerase I inhibitor added to Novartis pipeline

Nov. 7, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...